IDEXX Laboratories Q3 2024 Adj EPS $2.79 Beats $2.68 Estimate, Sales $975.54M Miss $979.18M Estimate
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories reported Q3 2024 earnings per share of $2.79, surpassing the analyst estimate of $2.68, marking a 12.05% increase from last year. However, sales of $975.54 million slightly missed the $979.18 million estimate, though they increased by 6.56% from the previous year.
October 31, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IDEXX Laboratories' Q3 2024 earnings per share exceeded expectations, but sales slightly missed estimates. The EPS beat may positively influence short-term stock prices, despite the sales miss.
The positive earnings per share surprise is likely to have a more significant impact on the stock price than the slight sales miss. Investors often react more strongly to EPS beats, which can drive short-term stock price increases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100